Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to $6.5 million.

  • Ani Pharmaceuticals' Other Working Capital Changes rose 41559.9% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 5047.18%. This contributed to the annual value of -$2.1 million for FY2024, which is 12361.62% down from last year.
  • Ani Pharmaceuticals' Other Working Capital Changes amounted to $6.5 million in Q3 2025, which was up 41559.9% from -$9.8 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $8.4 million during Q4 2023, with a 5-year trough of -$9.8 million in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' median Other Working Capital Changes value was -$219000.0 (recorded in 2021), while the average stood at $427421.1.
  • Data for Ani Pharmaceuticals' Other Working Capital Changes shows a peak YoY increase of 41559.9% (in 2025) and a maximum YoY decrease of 221957.55% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Other Working Capital Changes stood at $1.3 million in 2021, then soared by 163.91% to $3.4 million in 2022, then soared by 145.36% to $8.4 million in 2023, then tumbled by 79.79% to $1.7 million in 2024, then skyrocketed by 281.22% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, -$9.8 million for Q2 2025, and $3.9 million during Q1 2025.